Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study-Reference-Cited by-同舟云学术

Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study

Published:1996-06 Issue:6 Volume:103 Page:699-715
ISSN:0300-9564
Container-title:Journal of Neural Transmission
language:en
Short-container-title:J. Neural Transmission

Author:

Przuntek H.,Welzel D.,Gerlach M.,Bl�mner E.,Danielczyk W.,Kaiser H. -J.,Kraus P. H.,Letzel H.,Riederer P.,�berla K.

Publisher

Springer Science and Business Media LLC

Subject

Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/BF01271230.pdf

Reference42 articles.

1. Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, p 205

2. Bakheit AMO, Henderson LM, Moore AP, Simpson JA, Thomas M (1990) Long-term double masked trial of early treatment with L-Dopa plus bromocriptine versus L-Dopa alone in Parkinson's disease. Eur Neurol 30: 108?111

3. Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293?299

4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415?455

5. Boomsma F, Meerwaldt JD (1989) Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 236: 223?230

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose–response relationship of levodopa with dyskinesia in Parkinson's disease: A systematic review and meta-analysis;Heliyon;2024-03

2. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach;Expert Review of Neurotherapeutics;2023-01-02

3. Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease;International Journal of Molecular Sciences;2022-10-27

4. Effect of Dopamine Agonists on Sleep;Sleep and Neuropsychiatric Disorders;2022

5. Medical treatment of the motor features of Parkinson disease;Principles and Practice of Movement Disorders;2021